2,4,5-triamino-6-benzyloxy-pyrimidine | 19916-72-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 2,4,5-triamino-6-benzyloxy-pyrimidine
• 英文别名: NU6040；4-(benzyloxy)pyrimidine-2,5,6-triamine；6-(benzyloxy)pyrimidine-2,4,5-triamine；2,4,5-triamino-6-benzyloxypyrimidine；6-benzyloxy-2,4,5-triaminopyrimidine；6-benzyloxy-pyrimidine-2,4,5-triamine；2,5,6-Triamino-4-Benzyloxypyrimidine；6-phenylmethoxypyrimidine-2,4,5-triamine
• CAS: 19916-72-4
• 化学式: C₁₁H₁₃N₅O
• 分子量: 231.257
• InChiKey: QGOLEGLENLEGAL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  113
• 氢给体数：
  3
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  2,4,5-triamino-6-benzyloxy-pyrimidine 在 potassium permanganate 、 air 、 sodium ascorbate 作用下， 以 phosphate buffer 、 N,N-二甲基乙酰胺 、 丙酮 为溶剂， 反应 9.0h， 生成 2-amino-O⁴-benzylpteridine-6-carboxylic acid
  参考文献：
  名称：

  2-Amino-O⁴-benzylpteridine Derivatives:  Potent Inactivators of O⁶-Alkylguanine-DNA Alkyltransferase

  摘要：

  2-Amino-O-4-benzylpteridine (1), 2-amino-O-4-benzyl-6,7-dimethylpteridine (2), 2-amino-O-4- benzyl-6-hydroxymethylpteridine (4), 2-amino-O-4-benzylpteridine-6-carboxylic acid (5), 2-amino-O-4-benzyl-6-formylpteridine (6), and O-4-benzylfolic acid (7) are shown to be as potent or more potent inactivators of the human DNA repair protein O-6-alkylguanine-DNA alkyltransferase (alkyltransferase) in vitro than O-6-benzylguanine, the prototype alkyltransferase inactivator currently in clinical trials. Additionally, the negatively charged (at physiological pH) inactivators 2-amino-O-4-benzylpteridine-6-carboxylic acid (5) and O-4-benzylfolate (7) are far more water soluble than O-6-benzylguanine. The activity of O-4-benzylfolic acid (7) is particularly noteworthy because it is roughly 30 times more active than O-6-benzylguanine against the wild-type alkyltransferase and is even capable of inactivating the P140K mutant alkyltransferase that is resistant to inactivation by O-6-benzylguanine. All the pteridine derivatives except 2-amino-O-4-benzylpteridine-6-carboxylic acid are effective in enhancing cell killing by 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU). However, the effectiveness of O-4-benzylfolate as an adjuvant for cell killing by BCNU appears to be a function of a cell's alpha-folate receptor expression. Thus, O-4-benzylfolate is least effective as an adjuvant in A549 cells (which express little if any receptor), is moderately effective in HT29 cells (which express low levels of the receptor), but is very effective in KB cells (which are known to express high levels of the alpha-folate receptor). Therefore, O-4-benzylfolic acid shows promise as an agent for possible tumor-selective alkyltransferase inactivation, which suggests it may prove to be superior to O-6-benzylguanine as a chemotherapy adjuvant.

  DOI：

  10.1021/jm049758+
• 作为产物：
  描述：

  (E)-6-(benzyloxy)-5-((4-chlorophenyl)diazenyl)pyrimidine-2,4-diamine 在 溶剂黄146 、 锌 作用下， 以 乙醇 为溶剂， 反应 2.0h， 以44%的产率得到2,4,5-triamino-6-benzyloxy-pyrimidine
  参考文献：
  名称：

  三唑并嘧啶被鉴定为可逆性髓过氧化物酶抑制剂

  摘要：

  髓过氧化物酶是一种哺乳动物过氧化物酶，作为抗微生物第一反应者参与免疫系统，可以产生次氯酸以应对入侵的病原体。由于次氯酸以及其他活性自由基的长期产生，髓过氧化物酶与多种慢性病理性疾病有关。开发了高通量筛选和分类方案来鉴定髓过氧化物酶的可逆抑制剂，以用于治疗动脉粥样硬化等慢性疾病。描述了可逆髓过氧化物酶抑制剂 7-(benzyloxy)-3 H- [1,2,3]triazolo[4,5- d ]pyrimidin-5-amine的鉴定和表征。

  DOI：

  10.1039/c7md00268h

文献信息

• HAIR DYE AGENT COMPRISING AMINOPYRIMIDINE DERIVATIVES
  申请人：Henkel AG & Co. KGaA

  公开号：US20150209258A1

  公开（公告）日：2015-07-30

  The present application relates to agents for dyeing keratin fibers, in particular human hair, the agent including a cosmetic carrier and at least a compound of formula (I)

  本申请涉及染色角蛋白纤维的药剂，特别是人类头发，该药剂包括化妆品载体和至少一种符合式(I)的化合物。
• Synthesis of potential antifilarial agents 2 . methyl 2-substituted purine 8-carbamates and related compounds
  作者：Siya Ram、William Evans、Dean S. Wise、Leroy B. Townsend、John W. Mccall

  DOI：10.1002/jhet.5570260427

  日期：1989.7

  A series of methyl 2-substituted purine 8-carbamates was prepared and evaluated for antifilarial activity. These purines were synthesized as aza congeners of benzimidazole carbamates which have shown significant anthelmintic activity to determine the effect that this modification might have on anthelmintic activity. The compounds were tested against the filarial infection, B. pahangi, in jirds. None

  制备了一系列甲基2-取代的嘌呤8-氨基甲酸酯，并评估了其抗丝活性。这些嘌呤被合成为苯并咪唑氨基甲酸酯的氮杂同类物，其显示出显着的驱虫活性，从而确定该修饰对驱虫活性的影响。测试了这些化合物对丝状菌丝状芽孢杆菌（B. pahangi）的抵抗作用。在这项研究中制备的化合物均未显示出抗丝活性。
• Cyclin dependent kinase inhibitors
  申请人：Cancer Research Campaign Technology Limited

  公开号：US06677345B1

  公开（公告）日：2004-01-13

  A range is disclosed of pyrimidine derivatives (I) which can act as inhibitors of cyclin dependent kinases (CDK's) and which thereby can provide useful therapeutic compounds for use in treatment of tumours or other cell proliferation disorders. The compounds of this invention bind to CDK molecules in a manner that appears to differ from that of known CDK inhibitors such as olomoucine and roscovitine. In formula (I), X is O, S or CHRx where Rx is H or C1-4 alkyl; D is H or NZ1Z2 where Z1 and Z2 are each independently H, C1-4 alkyl, C1-4 hydroxyalkyl, optionally substituted aryl or optionally substituted aralkyl; A is selected from H, C1-4 alkyl, C1-4 alkoxy, hydroxy, CH2(CH2)nOH (n=1-4), and NRa1Ra2 where Ra1 and Ra2 are each independently H or C1-4 alkyl; Y is or includes an optionally substituted 4- to 8-membered carbocyclic or heterocyclic ring; D′ is H or NZ3Z4 where Z3 and Z4 are each independently H, C1-4 alkyl, C1-4 hydroxyalkyl, optionally substituted aryl or optionally-substituted aralkyl; E is selected from NO, NO2, N═N—Ar where Ar is an optionally substituted aryl or optionally substituted aralkyl, NRe1Re2 or Nre1Nre2Re3 (Re1, Re2 and Re3 each being independently H, C1-4 alkyl, C1-4 hydroxyalkyl, an optionally substituted aryl or an optionally substituted aralkyl), C(Re)═U (Re being hydrogen, C1-4 alkyl or substituted alkyl, e.g. hydroxyalkyl, or an unsubstituted or substituted aryl or aralkyl, e.g. benzyl, and U being selected from O, Nre′, NORe′ and N—NRe′Re″ where Re′ and Re″ are each independently H, C1-4 alkyl or CONH2), T, CH2T, CHT2 and CT3, where T is a halide I, Br, Cl or F.

  本发明公开了一系列嘧啶衍生物(I)，可以作为细胞周期依赖性激酶（CDK's）的抑制剂，并因此可以提供用于治疗肿瘤或其他细胞增殖障碍的有用治疗化合物。本发明的化合物以一种似乎与已知的CDK抑制剂（如olomoucine和roscovitine）不同的方式结合到CDK分子上。在式(I)中，X是O、S或CHRx，其中Rx是H或C1-4烷基；D是H或NZ1Z2，其中Z1和Z2分别独立地是H、C1-4烷基、C1-4羟基烷基、可选取代芳基或可选取代芳基烷基；A从H、C1-4烷基、C1-4烷氧基、羟基、CH2(CH2)nOH（n=1-4）和NRa1Ra2中选择，其中Ra1和Ra2分别独立地是H或C1-4烷基；Y是或包括一个可选取代的4-至8-成员碳环或杂环；D′是H或NZ3Z4，其中Z3和Z4分别独立地是H、C1-4烷基、C1-4羟基烷基、可选取代芳基或可选取代芳基烷基；E从NO、NO2、N═Ar（其中Ar是可选取代的芳基或可选取代的芳基烷基）、NRe1Re2或Nre1Nre2Re3（Re1、Re2和Re3分别独立地是H、C1-4烷基、C1-4羟基烷基、可选取代芳基或可选取代芳基烷基）、C(Re)═U（Re为氢、C1-4烷基或取代烷基，例如羟基烷基，或未取代或取代的芳基或芳基烷基，例如苄基，U从O、Nre′、NORe′和N—NRe′Re″中选择，其中Re′和Re″分别独立地是H、C1-4烷基或CONH2）、T、CH2T、CHT2和CT3中选择，其中T是卤素I、Br、Cl或F。
• 8-Substituted O6-Benzylguanine, Substituted 6(4)-(Benzyloxy)pyrimidine, and Related Derivatives as Inactivators of Human O6-Alkylguanine-DNA Alkyltransferase
  作者：Mi-Young Chae、Kristin Swenn、Sreenivas Kanugula、M. Eileen Dolan、Anthony E. Pegg、Robert C. Moschel

  DOI：10.1021/jm00002a018

  日期：1995.1

  Several 8-substituted O6-benzylguanines, 2- and/or 8-substituted 6-(benzyloxy)purines, substituted 6(4)-(benzyloxy)pyrimidines, and a 6-(benzyloxy)-s-triazine were tested for their ability to inactivate the human DNA repair protein, O6-alkylguanine-DNA alkyltransferase (AGT, alkyltransferase). Two types of compounds were identified as being significantly more effective than O6-benzylguanine (the prototype

  测试了几种8-取代的O6-苄基鸟嘌呤，2-和/或8-取代的6-（苄氧基）嘌呤，取代的6（4）-（苄氧基）嘧啶和6-（苄氧基）-s-三嗪的能力。使人类DNA修复蛋白O6-烷基鸟嘌呤-DNA烷基转移酶（AGT，烷基转移酶）失活。已鉴定出两种类型的化合物在使人HT29结肠肿瘤细胞提取物中的AGT失活方面比O6-苄基鸟嘌呤（原型低分子量灭活剂）明显更有效。它们是在8位带有吸电子基团的8-取代的O6-苄基鸟嘌呤（例如8-氮杂-O6-苄基鸟嘌呤和O6-苄基-8-溴鸟嘌呤）和5-取代的2,4-二氨基-6-（苄氧基）在5位带有吸电子基团的嘧啶（例如2,4-二氨基-6-（苄氧基）-5-亚硝基和2，4-二氨基-6-（苄氧基）-5-硝基嘧啶）。在完整的HT29结肠肿瘤细胞中，后者的衍生物在灭活AGT方面比O6-苄基鸟嘌呤更有效。如果这些类型的嘌呤和嘧啶没有表现出不希望的毒性，则它们可以优于O6-苄基鸟嘌呤作为用
• [EN] METHODS FOR SYNTHESIZING MOLYBDOPTERIN PRECURSOR Z DERIVATIVES<br/>[FR] PROCÉDÉS DE SYNTHÈSE DE DÉRIVÉS Z DE PRÉCURSEUR DE MOLYBDOPTÉRINE
  申请人：ALEXION PHARMA INC

  公开号：WO2012112922A1

  公开（公告）日：2012-08-23

  Provided herein are synthetic methods for preparing a compound of formula (I): Also provided herein are synthetic methods for preparing a compound of formula (XIII): The disclosure also provides useful intermediates, derivatives, prodrugs, and pharmaceutically acceptable salts, solvates and hydrates of the formula (I) and formula (XIII) compounds. These compounds are useful for treating diseases associated with molybdenum cofactor deficiency.

  本文提供了制备式(I)化合物的合成方法。本文还提供了制备式(XIII)化合物的合成方法。本公开还提供了式(I)和式(XIII)化合物的有用中间体、衍生物、前药和药用可接受的盐、溶剂合物和水合物。这些化合物可用于治疗与钼辅因子缺乏相关的疾病。